Thrombosis and Haemostasis, Inhaltsverzeichnis Thromb Haemost 1966; 16(01/02): 302-310DOI: 10.1055/s-0038-1655564 Originalarbeiten — Original Articles — Travaux Originaux Schattauer GmbH Distribution, Half Life Time and Placental Transfer of the Protease Inhibitor Trasylol F. K Beller M. D. *) 1 Department of Obstetrics and Gynecology, New York University School of Medicine , M. D Epstein M. D. **) 1 Department of Obstetrics and Gynecology, New York University School of Medicine , H Kaller ***) 1 Department of Obstetrics and Gynecology, New York University School of Medicine › InstitutsangabenArtikel empfehlen Abstract Artikel einzeln kaufen Summary A method is described for an assay of Trasylol in the circulation. By this method it was found that Trasylol disappears rapidly from the circulation. The half life time of elimination is approximately 150 minutes. The placental barrier is not crossed by this substance. Volltext Referenzen References 1 Anderer F. A, Hornle S. Strukturuntersuchungen anKallikrein-Inaktivator aus Rinderlunge. I. Molekulargewicht, Endgruppenanalyse und Aminosäure-Zusammensetzung. Z. Naturforsch 20: 451 1965; 2 Astrup T. Lung tissue as a proteolytic inhibitor. Acta physiol. scand 26: 243 1952; 3 Auhagen J. Verteilung und Elimination von Trasylol bei der Maus. Dissertation. Düsseldorf 1964 4 Beck E, Schmutzler R, Duckert F. Inhibition of fibrinolysis and fibrinogenolysis in man: comparison of E-amino-caproic-acid and Kallikrein inhibitor. Thrombos. Diathes. hemorrh. (Stuttg.) 10: 106 1963; 5 Beller F. K. Treatment of coagulation disorders in pregnancy. Clin. Obstet. Gynec 7: 372 1964; 6 Beller F. K, Douglas G. W, Epstein M. D. The fibrinolytic system in the newborne. (Inpress.) 7 Johnson A. V. Tse. In: Tocantis, L. and Kazal, Blood coagulation, hemorrhage and thrombosis. Grune and Stratton; London, New York: 1965 8 Kaller H. Tierexperimentelle Untersuchungen über Wirkungsdauer und Elimination von Trasylol. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak 246: 92 1963; 9 Kraut H, Bhargava N, Schidtz F, Zimmermann H. Versuche zur Isolierung des Kallikrein -Inaktivators IV. Hoppe-Seylers Z. physiol. Chem 334: 230 1963; 10 Kraut H, Frey E. K, Werle E. Über die Inaktivierung des Kallikreins. Hoppe-Seylers Z. physiol. Chem 192: 1 1930; 11 Kunitz M, Northrop J. H. Isolation from beef pancreas of crystalline trypsinogen, trypsin, atrypsin inhibitor and an inhibitor-Trypsin. J. gen. Physiol 19: 991 1936; 12 Marx R, demente P, Werle E, Appel W. Zum Problem eines Antidots in der internen Thrombotherapie mit fibrinolytika. Blut 5: 367 1959; 13 Marx R. Wirkungsweise der Fibrinolytica und Antifibrinolytica. Thrombos. Diathes. hemorrh 7 (Suppl. 03) 27 1963; 14 Werle E, Trautschold J. Bestimmung des Kallikrein-Inaktivators. ,,Trasylol” im Blut und in Organen und seine Verteilung nach Injektionen. Münch, med. Wschr 103: 773 1961;
